Candriam Luxembourg S.C.A. acquired a new position in shares of Immunomedics Inc. (NASDAQ:IMMU) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 185,000 shares of the biopharmaceutical company’s stock, valued at approximately $429,000.
Several other large investors have also modified their holdings of IMMU. Creative Planning increased its stake in shares of Immunomedics by 0.9% in the second quarter. Creative Planning now owns 58,485 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 510 shares during the last quarter. venBio Select Advisor LLC purchased a new position in shares of Immunomedics during the first quarter valued at $2,626,000. Opaleye Management Inc. increased its position in shares of Immunomedics by 356.9% in the first quarter. Opaleye Management Inc. now owns 1,325,000 shares of the biopharmaceutical company’s stock valued at $3,313,000 after buying an additional 1,035,000 shares in the last quarter. Finally, Sabby Management LLC purchased a new position in shares of Immunomedics during the first quarter valued at $182,240,000. 53.79% of the stock is owned by hedge funds and other institutional investors.
Shares of Immunomedics Inc. (NASDAQ:IMMU) remained flat at $2.50 on Wednesday. The company’s stock had a trading volume of 1,258,683 shares. The company’s 50-day moving average is $2.96 and its 200-day moving average is $3.04. Immunomedics Inc. has a 12 month low of $1.61 and a 12 month high of $5.44. The company’s market cap is $239.66 million.
Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.06. On average, analysts forecast that Immunomedics Inc. will post ($0.47) EPS for the current year.
Several research analysts recently weighed in on IMMU shares. Jefferies Group started coverage on shares of Immunomedics in a report on Thursday, October 6th. They issued a “buy” rating and a $5.50 target price for the company. Zacks Investment Research raised shares of Immunomedics from a “strong sell” rating to a “hold” rating and set a $2.75 target price for the company in a report on Friday, October 7th. Finally, Wells Fargo & Co. downgraded shares of Immunomedics from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 21st.
In other Immunomedics news, Director Mary E. Paetzold sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $2.98, for a total value of $44,700.00. Following the completion of the transaction, the director now owns 82,474 shares of the company’s stock, valued at $245,772.52. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Don C. Stark sold 9,900 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $2.97, for a total transaction of $29,403.00. Following the completion of the transaction, the director now directly owns 55,848 shares of the company’s stock, valued at approximately $165,868.56. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics Inc. (NASDAQ:IMMU).
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.